This page shows the latest Alessandro Riva news and features for those working in and with pharma, biotech and healthcare.
Company has own bispecific antibody platform. Indian pharma company Glenmark has appointed Alessandro Riva as the chief executive of its new spin-off company focused on innovative medicines. ... In a statement, Riva said he was excited to join a company
Alessandro Riva, MD, Gilead's executive vice president, Oncology Therapeutics &Head, Cell Therapy said: “This research collaboration adds an additional new platform to our current capabilities in research and cell manufacturing,
Zykadia has proven to be an important treatment option for ALK+ NSCLC patients who have progressed following treatment with crizotinib," said Novartis head of oncology development and medical affairs, Alessandro Riva.
established. Alessandro Riva, managing director and global head for Novartis' oncology development and medical affairs, said: “For more than 25 years, medical developments have been limited for AML patients and the
Alessandro Riva, global head of oncology development and medical affairs for Novartis's oncology business, said: "We are committed to working with the FDA as they continue to review the LBH589
Alessandro Riva, interim president of Novartis Oncology and global head of oncology development and medical affairs, said: "These results strengthen our understanding of this rare endocrine disorder and suggest pasireotide LAR
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Gilead Sciences has promoted Dr Alessandro River from senior vice president, haematology and oncology therapeutic area head, to executive vice president, oncology therapeutics. ... Dr Riva joined the biopharmaceutical group in January 2017, and his
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...